Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
March 4th 2024In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Listen
FDA to Review Inavolisib Combo for HR-Positive, HER2-Negative Breast Cancer
May 22nd 2024The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Read More